Brad Feldman, MD
Ophthalmology · Philadelphia, PANPI 1750554507
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $18,438 of the $21,830 with a category attached, or 84.5%. Amgen accounts for 90.2% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $10,218 and has fallen 89.4% since, to $1,084 in 2025. Among ophthalmology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 50 payments — averaging $436.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$20K
- Alcon$1K
- Johnson & Johnson Surgical Vision, Inc.$174
- AbbVie$165
- Astellas Pharma US Inc$152
- Biotissue Holdings Inc.$117
- plus $358 from 9 others
Across 5 payments — averaging $2293.80 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch & Lomb Americas Inc.$7K
- AbbVie$5K
What the payments were for
- Consulting fees$18,43884%
- Travel & lodging$1,2576%
- Food & beverage$1,9519%
- Education$1201%
- Gifts$640%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 5 | $19,694 |
| Alcon | 19 | $1,170 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $174 |
| AbbVie | 4 | $165 |
| Astellas Pharma US Inc | 2 | $152 |
| Biotissue Holdings Inc. | 2 | $117 |
| Glaukos Corporation | 2 | $87 |
| Rxsight Inc | 3 | $62 |
| Carl Zeiss Meditec USA, Inc. | 1 | $45 |
| Thea Pharma Inc. | 2 | $40 |
| Tarsus Pharmaceuticals, Inc. | 1 | $36 |
| Dompe US, Inc. | 1 | $27 |
| Ocular Therapeutix, Inc. | 2 | $24 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Dutch Ophthalmic, USA | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$481
- AcrySof IQ VIVITY$144
- Contoura Vision$136
- Izervay$132
- Wavelight Plus$108
How this compares
$21,830 in reported general payments places this provider in the 90th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 173 | $181,737 |
| Cyclosporine | 129 | $56,291 |
| XiidraLifitegrast | 54 | $44,827 |
| VyzultaLatanoprostene Bunod | 53 | $28,795 |
| Prednisolone Acetate | 278 | $12,837 |
| Loteprednol Etabonate | 60 | $11,704 |
| MieboPerfluorohexyloctane/Pf | 14 | $10,571 |
| Latanoprost | 707 | $8,570 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 27 | $6,490 |
| RocklatanNetarsudil Mesylat/Latanoprost | 19 | $6,235 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 47 | $5,750 |
| RhopressaNetarsudil Mesylate | 15 | $5,379 |
| IyuzehLatanoprost/Pf | 15 | $5,319 |
| CombiganBrimonidine Tartrate/Timolol | 13 | $4,909 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 179 | $4,324 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Combigan | $165 | $186,646186 claims |
| AlconSimbrinza | $1,170 | $6,49027 claims |
| Thea Pharma Inc.Iyuzeh | $40 | $5,31915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 920 ophthalmology providers in Pennsylvania.
Other ophthalmology in Philadelphia
- Julia HallerPhiladelphia$1.5M
- Beeran MeghparaPhiladelphia$496K
- Jonathan MyersPhiladelphia$359K
- Mark BlecherPhiladelphia$357K
- Anton KolomeyerPhiladelphia$355K
- Durga BorkarPhiladelphia$150K
- Rachel NiknamPhiladelphia$142K
- Joseph MarkoffPhiladelphia$130K
- Leslie KatzPhiladelphia$105K
- Zeba SyedPhiladelphia$99K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.